Rinsho Ketsueki
Online ISSN : 1882-0824
Print ISSN : 0485-1439
ISSN-L : 0485-1439
Fluminant Hepatic Failure Induced by Intermediate Dose Methotrexate in a Case with Non-Hodgkin's Lymphoma
Ken KAITOToshio KATAYAMAMayumi YOSHIDAAtsushi SAITOMasayuki KOBAYASHIShigemasa OCHIAIShuichi MASUOKATakaki SHIMADAKaichi NISHIWAKIOsamu SAKAI
Author information
JOURNAL RESTRICTED ACCESS

1990 Volume 31 Issue 11 Pages 1862-1867

Details
Abstract
Methotrexate (MTX) is frequently used as an antifolatic agent in many malignant neoplasmas such as leukemia, lymphoma and osteosarcoma. The major side effects of MTX are liver and renal damages, bone marrow suppression and so on. But careful management and citrovorum factor resque could decrease the incidence and degree of these side effects. In this report, we described a patient with non-Hodgkin's lymphoma who developed and died of fulminant hepatic failure soon after the administration of intermediate dose MTX. Serological tests for HB virus were not changed throughout, and lymphocyte stimulation test for MTX was strongly positive. His autopsy revealed no inflamatory cell infiltration into the liver, but marked biliary congestion which is a distinctive feature of drug induced hepatitis. From above results, it was suggested that nature of this fulminant hepatic failure was an allergic reaction to MTX. There is no previous report which is concerning about MTX and fetal drug related hepatic failure.
Content from these authors
© 1990 The Japanese Society of Hematology
Previous article Next article
feedback
Top